# Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

> **NCT05185544** · — · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Sensitivity

## Interventions

- **OTHER:** Neoadjuvant pemetrexed and cisplatin chemotherapy

## Key facts

- **NCT ID:** NCT05185544
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185544, "Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05185544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*